Last reviewed · How we verify
Morphine D (DESOMORPHINE)
Morphine D (generic name: DESOMORPHINE) is a desomorphine drug. It is currently in Phase 2 development.
Desomorphine works by binding to opioid receptors in the brain, mimicking the action of natural opioids to produce pain relief.
Morphine D, also known as desomorphine, is a synthetic opioid analgesic developed by Paul Jolles in 1932. It is a small molecule drug classified under the desomorphine drug class. Desomorphine is not FDA-approved for any indications and its commercial status is unknown. Key safety considerations include its potential for abuse and dependence. As a potent opioid, it works by binding to opioid receptors in the brain, providing pain relief.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DESOMORPHINE |
|---|---|
| Drug class | desomorphine |
| Target | Opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain has special locks called opioid receptors. Desomorphine is a key that fits into these locks, sending a signal to your brain that says 'pain is gone.' This helps to reduce the sensation of pain, but it can also lead to dependence and addiction.
Approved indications
Common side effects
Key clinical trials
- An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity (Phase 3)
- Preoperative Dexamethasone Enhances Quality of Recovery After Laparoscopic Bariatric Surgery: A Prospective Observational Study (N/A)
- Intrathecal Dexmedetomidine Versus Intrathecal Morphine Inpatients Undergoing Cardiac Valve Replacement Surgeries: Effect on Postoperative Pain and Diaphragmatic Function (NA)
- The Effects of Colloid Pre-Loading on D-Dimer of the Mother and Her Baby During Cesarean Section Under Spinal Anesthesia for Mild Preeclampsia (Phase 2)
- The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial (Phase 2)
- Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) (Phase 3)
- The Comparison of Analgesia Methods Used for Spinal Surgery (NA)
- Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine D CI brief — competitive landscape report
- Morphine D updates RSS · CI watch RSS
Frequently asked questions about Morphine D
What is Morphine D?
How does Morphine D work?
What is the generic name of Morphine D?
What drug class is Morphine D in?
What development phase is Morphine D in?
What does Morphine D target?
Related
- Drug class: All desomorphine drugs
- Target: All drugs targeting Opioid receptor
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing